Alison Kanski

1 month ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Researchers may have identified a new targeted therapy approach for fibrolamellar carcinoma (FLC), a rare liver cancer that affects young people, using PLK1 inhibitors. FLC primarily occurs in adolescents and young adults without other liver damage or disease. In a study published in Gut last month, researchers described their efforts to identify PLK1 as a promising target for treating this type of cancer.

1 month ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – A case report of a mother and daughter who both carried germline ALK mutations and developed neuroblastoma highlighted the potential benefits of targeted therapy treatments and surveillance for patients with germline mutations in cancer predisposition genes.

1 month ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Amgen reported growth across its precision oncology portfolio in the first quarter of the year, led by the bispecific T-cell engager Blincyto (blinatumomab), and talked up two of its investigational oncology candidates for FGFR- and KRAS-mutant cancers. The firm's FGFRb-targeted monoclonal antibody, bemarituzumab, is undergoing testing in several studies involving patients with gastric cancers that overexpress FGFR2b.

1 month ago | precisionmedicineonline.com | Alison Kanski

CHICAGO – After Genentech's anti-TIGIT immunotherapy combination failed to meet its primary endpoint in a late-stage study, experts at the American Association for Cancer Research's annual meeting considered the future of this drug class in non-small cell lung cancer. Researchers reported the full data readout from the Phase III SKYSCRAPER-01 trial of tiragolumab plus Genentech's PD-L1 immunotherapy Tecentriq (atezolizumab) in first-line PD-L1-high advanced NSCLC at the meeting on Monday.

1 month ago | precisionmedicineonline.com | Alison Kanski

CHICAGO – In a Phase I trial, Boehringer Ingelheim's HER2 inhibitor zongertinib demonstrated promising activity in patients with HER2-mutant advanced non-small cell lung cancer who received different prior treatments and in those with activating HER2 mutations within and outside of the tyrosine kinase domain (TKD).